v3.26.1
Segment Reporting
3 Months Ended
Mar. 31, 2026
Segment Reporting  
Segment Reporting

13. Segment Reporting

The Company manages its operations as a single operating segment for the purpose of assessing performance and making operating decisions while focusing on the development and commercialization of innovative cardiovascular medicines. These operations, which are reported on a consolidated basis, are focused on a single product. The accounting policies of the single operating segment are the same as those described in the summary of significant accounting policies. The chief operating decision maker, or “CODM,” assesses performance of the Company’s single operating segment based on consolidated net loss. Net loss is used by the CODM to evaluate budget to actual analytics, which are used to monitor expenditures and ensure the Company is meeting established budgets. The CODM is the principal officer group, which includes the Company’s chief executive officer and chief financial officer.

The following table presents information about the Company’s significant segment expenses, as provided to the Company’s CODM, and includes a reconciliation to consolidated net loss:

Three months ended March 31, 

(in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

Revenue

$

238

$

Less:

Cost of product sales

14

Research and development, net of tax credits, excluding share-based compensation

2,850

4,547

General and administrative, excluding share-based compensation

 

4,187

 

4,430

Commercial, excluding share-based compensation

 

15,568

 

10,195

Share-based compensation expense

1,282

1,351

Interest income

 

(1,732)

(697)

Royalty financing interest expense

3,133

Note payable interest expense

1,002

935

Net loss

$

(26,066)

$

(20,761)

The measure of segment assets is reported on the balance sheet as total consolidated assets.